Assignee
MYRIAD GENETICS INC
US·115 granted patents·152 pending applications·1,852 citations·filing 1995–2025
Top patents by PatentIndex Score
267 records- 0198US5869242AMass spectrometry to assess DNA sequence polymorphismsMYRIAD GENETICS INC·Filed 1995·Granted Feb 9, 1999·350 cites·12 claims
- 0296US6251610B1Method for sequencing both strands of a double stranded DNA in a single sequencing reactionMYRIAD GENETICS INC·Filed 2000·Granted Jun 26, 2001·153 cites·1 claims
- 0395US12221656B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2022·Granted Feb 11, 2025·3 cites·18 claims
- 0495US6562576B2Yeast two-hybrid system and use thereofMYRIAD GENETICS INC·Filed 2002·Granted May 13, 2003·59 cites·28 claims
- 0593US9574229B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2016·Granted Feb 21, 2017·11 cites·41 claims
- 0693US9279156B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2013·Granted Mar 8, 2016·16 cites·18 claims
- 0792US6444419B1TMPRSS2 is a tumor suppressorMYRIAD GENETICS INC·Filed 2000·Granted Sep 3, 2002·32 cites·2 claims
- 0890US10876164B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Dec 29, 2020·5 cites·4 claims
- 0989US11174517B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2016·Granted Nov 16, 2021·4 cites·7 claims
- 1089US9976188B2Cancer biomarkersMYRIAD GENETICS INC·Filed 2017·Granted May 22, 2018·5 cites·8 claims
- 1189US5709999ALinked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted Jan 20, 1998·96 cites·35 claims
- 1288US10954568B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Mar 23, 2021·3 cites·4 claims
- 1388US5710001A17q-linked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted Jan 20, 1998·61 cites·35 claims
- 1488US2024182979A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2024·Application pending·0 cites
- 1587US10626449B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2017·Granted Apr 21, 2020·2 cites·13 claims
- 1686US11505832B2Method of using biomarkers and clinical variables for predicting chemotherapy benefitMYRIAD GENETICS INC·Filed 2020·Granted Nov 22, 2022·2 cites·20 claims
- 1786US10612098B2Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·15 claims
- 1886US6410725B1Method for extracting DNA from dried specimensMYRIAD GENETICS INC·Filed 2000·Granted Jun 25, 2002·22 cites·19 claims
- 1985US7410944B1Depression geneMYRIAD GENETICS INC·Filed 2006·Granted Aug 12, 2008·7 cites·12 claims
- 2085US6033857AChromosome 13-linked breast cancer susceptibility geneMYRIAD GENETICS INC·Filed 1998·Granted Mar 7, 2000·48 cites·8 claims
- 2184USD730981SFormMYRIAD GENETICS INC·Filed 2014·Granted Jun 2, 2015·36 cites·1 claims
- 2284US6166194ATMPRSS2 is a tumor suppressorMYRIAD GENETICS INC·Filed 1999·Granted Dec 26, 2000·38 cites·1 claims
- 2384US6087099AMethod for sequencing both strands of a double stranded DNA in a single sequencing reactionMYRIAD GENETICS INC·Filed 1997·Granted Jul 11, 2000·92 cites·6 claims
- 2484US5789206AMethod for ligating adaptors to nucleic acids which methods are useful for obtaining the ends of genesMYRIAD GENETICS INC·Filed 1995·Granted Aug 4, 1998·105 cites·2 claims
- 2584US2026063636A1Signatures for predicting cancer immune therapy responseMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 2683US11225685B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2020·Granted Jan 18, 2022·1 cites·20 claims
- 2783US7250497B2Large deletions in human BRCA1 gene and use thereofMYRIAD GENETICS INC·Filed 2003·Granted Jul 31, 2007·14 cites·20 claims
- 2882US7547804B2Compounds, compositions, and methods employing sameMYRIAD GENETICS INC·Filed 2005·Granted Jun 16, 2009·8 cites·26 claims
- 2982US7008941B2Reverse-turn mimetics and methods relating theretoMYRIAD GENETICS INC·Filed 2002·Granted Mar 7, 2006·11 cites·44 claims
- 3082US6841352B2Mating-based method for detecting protein—protein interactionMYRIAD GENETICS INC·Filed 2002·Granted Jan 11, 2005·12 cites·57 claims
- 3182US6551786B2Screen assay for selecting protein-protein interaction modulatorsMYRIAD GENETICS INC·Filed 2002·Granted Apr 22, 2003·16 cites·26 claims
- 3281US7338775B1Enzyme assay and use thereofMYRIAD GENETICS INC·Filed 2006·Granted Mar 4, 2008·9 cites·7 claims
- 3381US6653102B2Nucleic acid encoding a phosphatase 2C that interacts with Fe 65MYRIAD GENETICS INC·Filed 2001·Granted Nov 25, 2003·16 cites·4 claims
- 3481US2023111438A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 3580US9388472B2Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2014·Granted Jul 12, 2016·3 cites·36 claims
- 3680US6895337B1Method of identifying genomic rearrangementsMYRIAD GENETICS INC·Filed 2002·Granted May 17, 2005·8 cites·33 claims
- 3780US2025250643A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 3879US10519513B2Cancer BiomarkersMYRIAD GENETICS INC·Filed 2019·Granted Dec 31, 2019·1 cites·8 claims
- 3979US7422853B1RNA interference using a universal targetMYRIAD GENETICS INC·Filed 2003·Granted Sep 9, 2008·16 cites·34 claims
- 4079US7335468B2TSG101-GAG interaction and use thereofMYRIAD GENETICS INC·Filed 2003·Granted Feb 26, 2008·8 cites·8 claims
- 4179US5747282A17Q-linked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted May 5, 1998·61 cites·20 claims
- 4279US2023094830A1Signatures for predicting cancer immune therapy responseMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 4378US11174519B2Method of treating cancerMYRIAD GENETICS INC·Filed 2019·Granted Nov 16, 2021·0 cites·11 claims
- 4478US11021752B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD GENETICS INC·Filed 2014·Granted Jun 1, 2021·1 cites·10 claims
- 4578US10612099B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD GENETICS INC·Filed 2016·Granted Apr 7, 2020·1 cites·5 claims
- 4678US7195873B2Drug response marker in beta-1 adrenergic receptor geneMYRIAD GENETICS INC·Filed 2002·Granted Mar 27, 2007·9 cites·12 claims
- 4778US2022205046A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 4878US2022259675A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 4977US5693473ALinked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted Dec 2, 1997·66 cites·14 claims
- 5077US2025215509A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 267 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →